GlassScriptPhysician profile
Faraidoon D Golyan
NPI 1174559926
$10,266.38
in general payments reported to CMS, 2019-2025
26 companies · $5,772 in 2025
The $5,772 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,143 · 2020: $119 · 2021: $142 · 2022: $815 · 2023: $610 · 2024: $665 · 2025: $5,772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,374 · Food and Beverage: $2,546 · Travel and Lodging: $106 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,374.00 |
| Food and Beverage | $2,546.37 |
| Travel and Lodging | $106.28 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $4,888.20 | 2023-2025 | |
| Medtronic Vascular, INC. | $1,416.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $691.08 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $479.45 | 2022-2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $394.04 | 2022-2025 | Amvuttra |
| Astrazeneca Pharmaceuticals LP | $368.18 | 2019-2025 | Farxiga, Lokelma |
| Janssen Pharmaceuticals, INC | $357.43 | 2019-2024 | Xarelto |
| Abbott Laboratories | $297.28 | 2022-2024 | Freestyle Libre 3, Gallant |
| E.R. Squibb & Sons, L.L.C. | $201.55 | 2021-2025 | Eliquis, Camzyos |
| Preventice Services, LLC | $137.09 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $125.00 | 2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $117.51 | 2019-2023 | |
| Lundbeck LLC | $117.38 | 2019-2020 | |
| Scpharmaceuticals INC. | $116.79 | 2024-2025 | |
| Amarin Pharma, INC. | $100.16 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $88.33 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.57 | 2019-2023 | Jardiance |
| Edwards Lifesciences Corporation | $65.78 | 2019-2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $52.89 | 2022-2024 | Varithena Administration Pack |
| Regeneron Healthcare Solutions, INC. | $42.47 | 2019 | |
| Medtronic, INC. | $34.86 | 2022 | |
| Inspire Medical Systems, INC. | $28.04 | 2024 | Inspire |
| Bridgebio Pharma, INC. | $22.35 | 2025 | Attruby |
| Amgen INC. | $22.07 | 2024 | Repatha |
| Novo Nordisk INC | $20.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $5.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faraidoon Golyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.